Methyltestosterone

Source: Wikipedia, the free encyclopedia.

"Android (drug)" redirects here. For the drug used in the treatment of anemia, see
Androyd
.
Methyltestosterone
Clinical data
Trade namesAgoviron, Android, Metandren, Oraviron, Oreton, Testovis, Testred, Virilon, others
Other namesRU-24400; NSC-9701; 17α-Methyltestosterone; 17α-Methylandrost-4-en-17β-ol-3-one[1][2][3]
AHFS/Drugs.comMonograph
Pregnancy
category
  • AU: D
Routes of
administration		By mouth, buccal, sublingual[4][5][6]
Drug classAndrogen; Anabolic steroid
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability~70%[8]
Protein binding98%[9]
MetabolismLiver
Elimination half-life150 minutes (~2.5–3 hours)[8][10]
Duration of action1–3 days[9]
ExcretionUrine: 90%[9]
Feces: 6%[9][11]
Identifiers
  • (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
JSmol)
SMILES
  • C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C
  • InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1 checkY
  • Key:GCKMFJBGXUYNAG-HLXURNFRSA-N checkY
  (verify)

Methyltestosterone, sold under the brand names Android, Metandren, and Testred among others, is an

symptoms like hot flashes, osteoporosis, and low sexual desire in women, and to treat breast cancer in women.[4][5][12][13][14] It is taken by mouth or held in the cheek or under the tongue.[4][13][14][6]

anabolic effects, which make it useful for producing masculinization.[4][16]

Methyltestosterone was discovered in 1935 and was introduced for medical use in 1936.[6][17][18][19][4] It was made shortly after the discovery of testosterone and was one of the first synthetic AAS to be developed.[6][17][18] In addition to its medical use, methyltestosterone is used to improve physique and performance, although it is not as commonly used as other AAS for such purposes due to its androgenic effects, estrogenic effects, and risk of liver damage.[4] The drug is a controlled substance in many countries and so non-medical use is generally illicit.[4]

Uses

Medical

Methyltestosterone is or has been used in the treatment of

symptoms associated with menopause in women in the United States, but this formulation was discontinued and hence is no longer used.[14]

Methyltestosterone is less effective in inducing masculinization than testosterone, but is useful for maintaining established masculinization in adults.[20]

The dosages of methyltestosterone used are 10 to 50 mg/day in men for common medical uses like hypogonadism and delayed puberty as well as physique- and performance-enhancing purposes and 2.5 mg/day in women for menopausal symptoms.[4] Higher dosages of 50 to 200 mg/day have been used to treat women with inoperable breast cancer that has failed to respond to other therapies, although such dosages are associated with severe irreversible virilization.[4]

Androgen replacement therapy formulations and dosages used in men
Route Medication Major brand names Form Dosage
Oral Testosteronea – Tablet 400–800 mg/day (in divided doses)
Testosterone undecanoate Andriol, Jatenzo Capsule 40–80 mg/2–4× day (with meals)
Methyltestosteroneb Android, Metandren, Testred Tablet 10–50 mg/day
Fluoxymesteroneb Halotestin, Ora-Testryl, Ultandren Tablet 5–20 mg/day
Metandienoneb Dianabol Tablet 5–15 mg/day
Mesteroloneb Proviron Tablet 25–150 mg/day
Sublingual Testosteroneb Testoral Tablet 5–10 mg 1–4×/day
Methyltestosteroneb Metandren, Oreton Methyl Tablet 10–30 mg/day
Buccal Testosterone Striant Tablet 30 mg 2×/day
Methyltestosteroneb Metandren, Oreton Methyl Tablet 5–25 mg/day
Transdermal
 Testosterone AndroGel, Testim, TestoGel Gel 25–125 mg/day
Androderm, AndroPatch, TestoPatch Non-scrotal patch 2.5–15 mg/day
Testoderm Scrotal patch 4–6 mg/day
Axiron Axillary solution 30–120 mg/day
Androstanolone (DHT) Andractim Gel 100–250 mg/day
Rectal Testosterone Rektandron, Testosteronb Suppository 40 mg 2–3×/day
SC
Tooltip subcutaneous injection)		 Testosterone Andronaq, Sterotate, Virosterone Aqueous suspension 10–50 mg 2–3×/week
Testosterone propionateb Testoviron Oil solution 10–50 mg 2–3×/week
Testosterone enanthate Delatestryl Oil solution 50–250 mg 1x/1–4 weeks
Xyosted Auto-injector 50–100 mg 1×/week
Testosterone cypionate Depo-Testosterone Oil solution 50–250 mg 1x/1–4 weeks
Testosterone isobutyrate Agovirin Depot Aqueous suspension 50–100 mg 1x/1–2 weeks
Testosterone phenylacetateb Perandren, Androject Oil solution 50–200 mg 1×/3–5 weeks
Mixed testosterone esters Sustanon 100, Sustanon 250 Oil solution 50–250 mg 1×/2–4 weeks
Testosterone undecanoate Aveed, Nebido Oil solution 750–1,000 mg 1×/10–14 weeks
Testosterone buciclatea – Aqueous suspension 600–1,000 mg 1×/12–20 weeks
Implant Testosterone Testopel Pellet 150–1,200 mg/3–6 months
Notes: Men produce about 3 to 11 mg of testosterone per day (mean 7 mg/day in young men). Footnotes: a = Never marketed. b = No longer used and/or no longer marketed. Sources: See template.
Androgen replacement therapy formulations and dosages used in women
Route Medication Major brand names Form Dosage
Oral Testosterone undecanoate Andriol, Jatenzo Capsule 40–80 mg 1x/1–2 days
Methyltestosterone Metandren, Estratest Tablet 0.5–10 mg/day
Fluoxymesterone Halotestin Tablet 1–2.5 mg 1x/1–2 days
Normethandronea Ginecoside Tablet 5 mg/day
Tibolone Livial Tablet 1.25–2.5 mg/day
Prasterone (DHEA)b – Tablet 10–100 mg/day
Sublingual Methyltestosterone Metandren Tablet 0.25 mg/day
Transdermal
 Testosterone Intrinsa Patch 150–300 μg/day
AndroGel Gel, cream 1–10 mg/day
Vaginal
 Prasterone (DHEA) Intrarosa Insert 6.5 mg/day
Injection Testosterone propionatea Testoviron Oil solution 25 mg 1x/1–2 weeks
Testosterone enanthate Delatestryl, Primodian Depot Oil solution 25–100 mg 1x/4–6 weeks
Testosterone cypionate Depo-Testosterone, Depo-Testadiol Oil solution 25–100 mg 1x/4–6 weeks
Testosterone isobutyratea Femandren M, Folivirin Aqueous suspension 25–50 mg 1x/4–6 weeks
Mixed testosterone esters
 Climacterona Oil solution 150 mg 1x/4–8 weeks
Omnadren, Sustanon Oil solution 50–100 mg 1x/4–6 weeks
Nandrolone decanoate Deca-Durabolin Oil solution 25–50 mg 1x/6–12 weeks
Prasterone enanthatea Gynodian Depot Oil solution 200 mg 1x/4–6 weeks
Implant Testosterone Testopel Pellet 50–100 mg 1x/3–6 months
Notes:
Over-the-counter
. Sources: See template.
Androgen/anabolic steroid dosages for breast cancer
Route Medication Form Dosage
Oral Methyltestosterone Tablet 30–200 mg/day
Fluoxymesterone Tablet 10–40 mg 3x/day
Calusterone Tablet 40–80 mg 4x/day
Normethandrone Tablet 40 mg/day
Buccal Methyltestosterone Tablet 25–100 mg/day
SC
Tooltip subcutaneous injection)		 Testosterone propionate Oil solution 50–100 mg 3x/week
Testosterone enanthate Oil solution 200–400 mg 1x/2–4 weeks
Testosterone cypionate Oil solution 200–400 mg 1x/2–4 weeks
Mixed testosterone esters
 Oil solution 250 mg 1x/week
Methandriol Aqueous suspension 100 mg 3x/week
Androstanolone (DHT) Aqueous suspension 300 mg 3x/week
Drostanolone propionate Oil solution 100 mg 1–3x/week
Metenolone enanthate Oil solution 400 mg 3x/week
Nandrolone decanoate Oil solution 50–100 mg 1x/1–3 weeks
Nandrolone phenylpropionate Oil solution 50–100 mg/week
Note: Dosages are not necessarily equivalent. Sources: See template.

Non-medical

Methyltestosterone is used for

powerlifters, although it is not commonly used relative to other AAS for such purposes.[4]

Available forms

See also: Esterified estrogens/methyltestosterone and Conjugated estrogens/methyltestosterone

Methyltestosterone is typically used as an oral medication.[6] It is also available under the brand names Metandren and Oreton Methyl for use specifically by buccal or sublingual administration.[6][21] Methyltestosterone is available in the form of 2, 5, 10, and 25 mg oral tablets.[22][23] It was also available in combination with estrogens as esterified estrogens/methyltestosterone (0.625 mg/1.25 mg, 1.25 mg/2.5 mg) and conjugated estrogens/methyltestosterone (0.625 mg/5.0 mg, 1.25 mg/10 mg).[22]

Contraindications

Methyltestosterone should be used with caution in women and children, as it can cause irreversible virilization.

epiphyseal closure and thereby produce short stature in children and adolescents.[4] It can worsen symptoms in men with benign prostatic hyperplasia.[4] Methyltestosterone should not be used in men with prostate cancer, as androgens can accelerate tumor progression.[4] The drug should be used with caution in patients with pre-existing hepatotoxicity, due to its own potential for hepatotoxicity.[4]

Side effects

See also: Anabolic steroid § Adverse effects

menstrual disturbances and reversible infertility.[4][24] In men, the drug may also cause hypogonadism, testicular atrophy, and reversible infertility at sufficiently high dosages.[4][24]

Methyltestosterone can sometimes cause

suicidality, delusions, and psychosis have all been associated with very high dosages of AAS.[26]

Interactions

anabolic to androgenic activity and reduce its rate of androgenic side effects.[4]

Pharmacology

Pharmacodynamics

Androgenic vs. anabolic activity ratio
of androgens/anabolic steroids
Medication Ratioa
Testosterone ~1:1
Androstanolone (DHT) ~1:1
Methyltestosterone ~1:1
Methandriol ~1:1
Fluoxymesterone 1:1–1:15
Metandienone 1:1–1:8
Drostanolone 1:3–1:4
Metenolone 1:2–1:30
Oxymetholone 1:2–1:9
Oxandrolone 1:3–1:13
Stanozolol 1:1–1:30
Nandrolone 1:3–1:16
Ethylestrenol 1:2–1:19
Norethandrolone 1:1–1:20
Notes: In rodents. Footnotes: a = Ratio of androgenic to anabolic activity. Sources: See template.

As an AAS, methyltestosterone is an

fluid retention.[17][27] The drug possesses negligible progestogenic activity.[4][24]

Due to its combined disadvantages of a relatively poor ratio of anabolic to androgenic activity, unusually high estrogenicity, and the potential for hepatotoxicity (as with other 17α-alkylated AAS), methyltestosterone has not been used as commonly as many other AAS either in medicine or for physique- or performance-enhancing purposes.[4]

Pharmacokinetics

Absorption

Methyltestosterone has dramatically improved

well-absorbed from the gastrointestinal tract.[8] Methyltestosterone can also be taken buccally or sublingually.[4][8] Although effective orally, methyltestosterone is more effective by these non-oral routes, which are said to approximately double its bioavailability and require half the oral dosage.[4][8][21]

Circulating levels of methyltestosterone with administration of 1.25 to 2.5 mg/day oral methyltestosterone in women are in the range of 20 to 30 ng/dL.[28] For comparison to testosterone, methyltestosterone is at least as potent as an AAS.[28] However, due to the large decrease in sex hormone-binding globulin (SHBG) levels and hence increase in free unbound testosterone caused by methyltestosterone, androgenic effects may be greater than reflected merely by methyltestosterone levels.[28]

Distribution

Methyltestosterone is highly

affinity for human serum sex hormone-binding globulin (SHBG), about 25% of that of testosterone and 5% of that of DHT.[4][29]

Metabolism

The

duration of action of methyltestosterone is said to be 1 to 3 days, and is described as relatively short among AAS.[9][30]

Excretion

Methyltestosterone is

conjugates and other metabolites, and 6% in feces.[9]

Chemistry

See also:
List of androgens/anabolic steroids § Testosterone derivatives

Methyltestosterone, also known as 17α-methyltestosterone or as 17α-methylandrost-4-en-17β-ol-3-one, is a

derivative of testosterone differing from it only in the presence of a methyl group at the C17α position.[1][2][4] Close synthetic relatives of methyltestosterone include metandienone (17α-methyl-δ1-testosterone) and fluoxymesterone (9α-fluoro-11β-hydroxy-17α-methyltestosterone).[4][24]

Derivatives

See also: 17α-Alkylated anabolic steroid § List of 17α-alkylated AAS

Methyltestosterone and ethyltestosterone (17α-ethyltestosterone) are the parent structures of all 17α-alkylated AAS. Major 17α-alkylated AAS include the testosterone derivatives fluoxymesterone, metandienone (methandrostenolone), and methyltestosterone and the DHT derivatives oxandrolone, oxymetholone, and stanozolol.[4][24]

Synthesis

A

intermediate proceeds as follows:[31][32]

History

Methyltestosterone was first synthesized in 1935 along with methandriol and mestanolone.[33][34][6][17][18] It was the second synthetic AAS to be developed, following mesterolone (1α-methyl-DHT) in 1934, and was the first 17α-alkylated AAS to be synthesized.[6][17][18] The drug was introduced for medical use in 1936.[19][4]

Society and culture

A confiscated capsule of illicit methyltestosterone.

Generic names

Methyltestosterone is the

Latin, methyltestosteron in German, and metiltestosterona in Spanish.[1][2][3] Methyltestosterone is also known by its former developmental code name NSC-9701.[35][3]

Brand names

Brand names under which methyltestosterone is or has been marketed for medical use include Afro, Agovirin, Android, Androral, Mesteron, Metandren, Methitest, Methyltestosterone, Methyl Testosterone, Oraviron, Oreton, Oreton Methyl, Testormon, Testovis, Testred, and Virilon, among others.[1][2][3][36]

With an estrogen

Main article: Esterified estrogens/methyltestosterone

Methyltestosterone is available at a low-dose in combination with esterified estrogens for the treatment of menopausal symptoms like hot flashes in women under the brand names Covaryx, Essian, Estratest, Menogen, and Syntest.[4][37]

Availability

Availability of methyltestosterone in countries throughout the world. Blue is currently or formerly marketed.

United States

See also: List of androgens/anabolic steroids available in the United States

Although it is not commonly used, methyltestosterone is one of the few AAS that remains available for medical use in the United States.[4][36] The others are testosterone, testosterone cypionate, testosterone enanthate, testosterone undecanoate, oxandrolone, oxymetholone, and fluoxymesterone.[36]

Other countries

Methyltestosterone has also been marketed in many other countries throughout the world.[1][2][3][4][38][39]

Methyltestosterone, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act and a schedule IV controlled substance in Canada under the Controlled Drugs and Substances Act.[40][41]

See also

References

  1. ^
    ISBN 978-1-4757-2085-3
    .
  2. ^
    ISBN 978-3-88763-075-1
    .
  3. ^ a b c d e f "Methyltestosterone".
  4. ^
    ISBN 978-0-9679304-7-3
    .
  5. ^
    ISBN 978-1-4200-4744-8
    .
  6. ^
    ISBN 978-3-319-46086-4
    .
  7. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-15.
  8. ^
    ISBN 978-1-60913-345-0
    .
  9. ^
    ISBN 978-0-8036-4581-3
    .
  10. ISBN 978-0-511-54522-1
    .
  11. ^
    ISBN 978-0-471-97639-4
    .
  12. ^
    ISBN 978-0-323-07824-5
    .
  13. ^ a b c "Android® C-III, Brand of Methyl TESTOSTERone" (PDF). Valeant Pharmaceuticals North America. U.S. Food and Drug Administration.
  14. ^ a b c "Esterified estrogens and methyltestosterone tablet, film coated". DailyMed. U.S. National Library of Medicine.
  15. PMID 18500378
    .
  16. ISBN 978-3-642-66353-6
    .
  17. ^
    ISBN 978-3-540-79088-4
    .
  18. ^
    PMID 11589254
    .
  19. ^ a b N.A.R.D. journal. National Association of Retail Druggists. July 1956.
  20. ISBN 978-1-4684-5036-1
    .
  21. ^
    ISBN 978-0-89970-160-8
    .
  22. ^
    ISBN 978-0-387-97972-4
    .
  23. ISBN 978-3-7091-5694-0
    .
  24. ^
    PMID 18500378
    .
  25. ISBN 978-0-08-093292-7
    .
  26. ISBN 978-1-4511-7861-6
    .
  27. ISBN 978-1-84214-311-7
    .
  28. ^
    S2CID 9872335
    .
  29. PMID 6539197
    .
  30. ISBN 978-0-323-07575-6
    .
  31. ISBN 978-0-470-39959-0
    .
  32. ISBN 978-81-312-2190-7
    .
  33. PMID 8674183
    .
  34. ISSN 0018-019X
    .
  35. ^
    ISBN 978-94-011-4439-1
    .
  36. ^ a b c "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 28 June 2017.
  37. ^ "Esterified Estrogens and Methyltestosterone (Oral Route) Description and Brand Names". Mayo Clinic.
  38. ISBN 978-3-7692-2114-5
    .
  39. ISBN 978-0-8155-1856-3
    .
  40. ISBN 978-1-4200-0346-8
    .
  41. ISBN 978-1-77172-066-3
    .

Further reading
Retrieved from "https://en.wikipedia.org/w/index.php?title=Methyltestosterone&oldid=1269339482"